Literature DB >> 25759125

Reactivation of persistent Epstein-Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBV-infected B lymphocytes with TRAbs on their surface.

Keiko Nagata1, Yuji Nakayama, Katsumi Higaki, Marika Ochi, Kyosuke Kanai, Michiko Matsushita, Satoshi Kuwamoto, Masako Kato, Ichiro Murakami, Takeshi Iwasaki, Eiji Nanba, Hiroshi Kimura, Kazuhiko Hayashi.   

Abstract

Epstein-Barr virus (EBV) is a ubiquitous virus that infects most adults latently. It persists in B lymphocytes and reactivates occasionally. Graves' disease is an autoimmune hyperthyroidism caused by thyrotropin receptor antibodies (TRAbs). We have reported that Graves' disease patients and healthy controls have EBV-infected lymphocytes that have TRAbs on their surface (TRAb(+)EBV(+) cells) in peripheral blood mononuclear cells (PBMCs). EBV reactivation is known to be associated with plasma cell differentiation and antibody production of B cells. In this study, we investigated whether TRAb(+)EBV(+) cells really produce TRAbs or not when persistent EBV is reactivated. We cultured PBMCs from 12 Graves' disease patients and 12 healthy controls for several days with cyclosporine A to expand the EBV-infected cell population, and then compared TRAb levels between EBV reactivation by 33 °C culture and EBV nonreactivation by 37 °C culture of PBMCs. Flow cytometry confirmed that all samples at day 0 (reactivation starting point) contained TRAb(+)EBV(+) cells. During 33 °C culture, EBV-reactivated cells with EBV-gp350/220 expression increased from about 1 to 4%. We quantified TRAb levels in culture fluids by radio-receptor assay, and detected an increased concentration for at least one sampling point at 33 °C (from days 0 to 12) for all patients and healthy controls. TRAb levels were significantly higher in supernatants of 33 °C culture than of 37 °C culture, and also significantly higher in supernatants from patients than those from controls. This study revealed TRAb production from TRAb(+)EBV(+) cells in response to reactivation induction of persistent EBV in different efficiencies between patients and controls.

Entities:  

Keywords:  Autoantibody; Graves'; disease; latent virus; pathogenesis; plasma cell differentiation

Mesh:

Substances:

Year:  2015        PMID: 25759125     DOI: 10.3109/08916934.2015.1022163

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  12 in total

Review 1.  A possible link between the Epstein-Barr virus infection and autoimmune thyroid disorders.

Authors:  Anna Dittfeld; Katarzyna Gwizdek; Marek Michalski; Romuald Wojnicz
Journal:  Cent Eur J Immunol       Date:  2016-10-25       Impact factor: 2.085

2.  Epstein-Barr Virus Lytic Reactivation Activates B Cells Polyclonally and Induces Activation-Induced Cytidine Deaminase Expression: A Mechanism Underlying Autoimmunity and Its Contribution to Graves' Disease.

Authors:  Keiko Nagata; Keisuke Kumata; Yuji Nakayama; Yukio Satoh; Hirotsugu Sugihara; Sayuri Hara; Michiko Matsushita; Satoshi Kuwamoto; Masako Kato; Ichiro Murakami; Kazuhiko Hayashi
Journal:  Viral Immunol       Date:  2017-03-23       Impact factor: 2.257

3.  Estradiol Affects Epstein-Barr Virus Reactivation-Induced Thyrotropin Receptor Antibody and Immunoglobulin Production in Graves' Disease Patients and Healthy Controls.

Authors:  Sayuri Hara; Keiko Nagata; Keisuke Kumata; Michiko Matsushita; Satoshi Kuwamoto; Masako Kato; Kazuhiko Hayashi
Journal:  Viral Immunol       Date:  2018-08-22       Impact factor: 2.257

4.  Human osteoclastogenesis in Epstein-Barr virus-induced erosive arthritis in humanized NOD/Shi-scid/IL-2Rγnull mice.

Authors:  Yosuke Nagasawa; Masami Takei; Mitsuhiro Iwata; Yasuko Nagatsuka; Hiroshi Tsuzuki; Kenichi Imai; Ken-Ichi Imadome; Shigeyoshi Fujiwara; Noboru Kitamura
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

5.  Production of thyrotropin receptor antibodies in acute phase of infectious mononucleosis due to Epstein-Barr virus primary infection: a case report of a child.

Authors:  Keiko Nagata; Keisuke Okuno; Marika Ochi; Keisuke Kumata; Hitoshi Sano; Naohiro Yoneda; Jun-Ichi Ueyama; Michiko Matsushita; Satoshi Kuwamoto; Masako Kato; Ichiro Murakami; Susumu Kanzaki; Kazuhiko Hayashi
Journal:  Springerplus       Date:  2015-08-27

6.  Graves' hyperthyroidism accompanied with acute hepatitis B virus infection: an extrahepatic manifestation?

Authors:  Wei Cui; Baocheng Deng; Wen Wang; Pei Liu
Journal:  Virol J       Date:  2016-05-20       Impact factor: 4.099

7.  Thyrotropin Receptor Antibody (TRAb)-IgM Levels Are Markedly Higher Than TRAb-IgG Levels in Graves' Disease Patients and Controls, and TRAb-IgM Production Is Related to Epstein-Barr Virus Reactivation.

Authors:  Keisuke Kumata; Keiko Nagata; Michiko Matsushita; Satoshi Kuwamoto; Masako Kato; Ichiro Murakami; Shuji Fukata; Kazuhiko Hayashi
Journal:  Viral Immunol       Date:  2016-08-16       Impact factor: 2.257

8.  Epstein-Barr Virus Lytic Reactivation Induces IgG4 Production by Host B Lymphocytes in Graves' Disease Patients and Controls: A Subset of Graves' Disease Is an IgG4-Related Disease-Like Condition.

Authors:  Keiko Nagata; Sayuri Hara; Yuji Nakayama; Katsumi Higaki; Hirotsugu Sugihara; Satoshi Kuwamoto; Michiko Matsushita; Masako Kato; Shunsuke Tanio; Kiyosuke Ishiguro; Kazuhiko Hayashi
Journal:  Viral Immunol       Date:  2018-09-17       Impact factor: 2.257

9.  Subclinical Epstein-Barr Virus Primary Infection and Lytic Reactivation Induce Thyrotropin Receptor Autoantibodies.

Authors:  Naohiro Tamoto; Keiko Nagata; Sayuri Hara; Yuji Nakayama; Satoshi Kuwamoto; Michiko Matsushita; Masako Kato; Kazuhiko Hayashi
Journal:  Viral Immunol       Date:  2019-10-03       Impact factor: 2.257

10.  Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Maria Camila Sierra-Cote; Estefanía Zapata-Bravo; Laura Valenzuela-Vallejo; Maria Alejandra Marin-Noriega; Pilar Uribe-Reina; Juan Pablo Terreros-Dorado; Marcela Gómez-Suarez; Karla Arteaga-Rivera; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.